Nuvation Bio Inc. Debt Securities, Unrealized Gain (Loss)
Nuvation Bio Inc. (NUVB) reported Debt Securities, Unrealized Gain (Loss) of -$463.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesUnrealizedGainLoss · last filed 2026-08-06
- Nuvation Bio Inc. debt securities, unrealized gain (loss) for the quarter ending 2026-06-30 was -$463.00K.
- Nuvation Bio Inc. debt securities, unrealized gain (loss) for the quarter ending 2026-03-31 was -$1.22M.
- Nuvation Bio Inc. debt securities, unrealized gain (loss) for the quarter ending 2025-12-31 was $958.00K.
- Nuvation Bio Inc. debt securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $501.00K, a 85.22% decline year-over-year.
- Nuvation Bio Inc. debt securities, unrealized gain (loss) for fiscal 2025 was $741.00K.
- Nuvation Bio Inc. debt securities, unrealized gain (loss) for fiscal 2024 was -$145.00K, a 102.54% decline from fiscal 2023.
- Nuvation Bio Inc. debt securities, unrealized gain (loss) for fiscal 2023 was $5.71M.
- Nuvation Bio Inc. debt securities, unrealized gain (loss) for fiscal 2022 was -$4.34M.
| Period end | Debt Securities, Unrealized Gain (Loss) 3 month | Debt Securities, Unrealized Gain (Loss) 3 month as first filed | Debt Securities, Unrealized Gain (Loss) 6 month | Debt Securities, Unrealized Gain (Loss) 9 month | Debt Securities, Unrealized Gain (Loss) 9 month as first filed | Debt Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$463.00K 10-Q · filed 2026-08-06 | -$1.69M 10-Q · filed 2026-08-06 | -$727.00K derived: sum of 3 quarters · filed 2026-08-06 | -$226.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | -$1.22M 10-Q · filed 2026-05-04 | -$264.00K derived: sum of 2 quarters · filed 2026-05-04 | $237.00K derived: sum of 3 quarters · filed 2026-05-04 | $12.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $958.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.46M derived: sum of 2 quarters · filed 2026-03-02 | $1.23M derived: sum of 3 quarters · filed 2026-08-06 | $741.00K 10-K · filed 2026-03-02 | ||
| 2025-09-30 | $501.00K 10-Q · filed 2025-11-03 | $276.00K derived: sum of 2 quarters · filed 2026-08-06 | -$217.00K 10-Q · filed 2025-11-03 | -$2.16M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | -$225.00K 10-Q · filed 2026-08-06 | -$718.00K 10-Q · filed 2026-08-06 | -$2.66M derived: sum of 3 quarters · filed 2026-08-06 | $732.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | -$493.00K 10-Q · filed 2026-05-04 | -$2.43M derived: sum of 2 quarters · filed 2026-05-04 | $957.00K derived: sum of 3 quarters · filed 2026-05-04 | $712.00K derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | -$1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.45M derived: sum of 2 quarters · filed 2026-03-02 | $1.21M derived: sum of 3 quarters · filed 2026-03-02 | -$145.00K 10-K · filed 2026-03-02 | ||
| 2024-09-30 | $3.39M 10-Q · filed 2025-11-03 | -$3.39M 10-Q · filed 2024-11-06 | $3.14M derived: sum of 2 quarters · filed 2025-11-03 | $1.79M 10-Q · filed 2025-11-03 | -$1.79M 10-Q · filed 2024-11-06 | $9.73M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$245.00K 10-Q · filed 2025-08-07 | -$1.59M 10-Q · filed 2025-08-07 | $6.34M derived: sum of 3 quarters · filed 2025-08-07 | $5.24M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | -$1.35M 10-Q · filed 2025-05-07 | $6.58M derived: sum of 2 quarters · filed 2025-05-07 | $5.49M derived: sum of 3 quarters · filed 2025-05-07 | $4.03M derived: sum of 4 quarters · filed 2025-05-07 | ||
| 2023-12-31 | $7.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $6.84M derived: sum of 2 quarters · filed 2025-03-06 | $5.38M derived: sum of 3 quarters · filed 2025-03-06 | $5.71M 10-K · filed 2025-03-06 | ||
| 2023-09-30 | -$1.10M 10-Q · filed 2024-11-06 | $1.10M 10-Q · filed 2023-11-02 | -$2.55M derived: sum of 2 quarters · filed 2024-11-06 | -$2.23M 10-Q · filed 2024-11-06 | $2.23M 10-Q · filed 2023-11-02 | $2.63M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$1.46M 10-Q · filed 2024-08-05 | $1.13M 10-Q · filed 2024-08-05 | $3.72M derived: sum of 3 quarters · filed 2024-08-05 | $2.58M derived: sum of 4 quarters · filed 2024-08-05 | ||
| 2023-03-31 | $2.59M 10-Q · filed 2024-05-14 | $5.18M derived: sum of 2 quarters · filed 2024-05-14 | $4.04M derived: sum of 3 quarters · filed 2024-05-14 | $3.28M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $2.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.45M derived: sum of 2 quarters · filed 2024-02-29 | $691.00K derived: sum of 3 quarters · filed 2024-02-29 | -$4.34M 10-K · filed 2024-02-29 | ||
| 2022-09-30 | -$1.14M 10-Q · filed 2023-11-02 | -$1.90M derived: sum of 2 quarters · filed 2023-11-02 | -$6.93M 10-Q · filed 2023-11-02 | -$8.51M derived: sum of 4 quarters · filed 2023-11-02 | ||
| 2022-06-30 | -$761.00K 10-Q · filed 2023-08-03 | -$5.79M 10-Q · filed 2023-08-03 | -$7.37M derived: sum of 3 quarters · filed 2023-08-03 | -$7.74M derived: sum of 4 quarters · filed 2023-08-03 | ||
| 2022-03-31 | -$5.03M 10-Q · filed 2023-05-04 | -$6.61M derived: sum of 2 quarters · filed 2023-05-04 | -$6.97M derived: sum of 3 quarters · filed 2023-05-04 | -$7.20M derived: sum of 4 quarters · filed 2023-05-04 | ||
| 2021-12-31 | -$1.57M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$1.94M derived: sum of 2 quarters · filed 2023-03-15 | -$2.17M derived: sum of 3 quarters · filed 2023-03-15 | -$2.74M 10-K · filed 2023-03-15 | ||
| 2021-09-30 | -$369.00K 10-Q · filed 2022-11-03 | -$593.00K derived: sum of 2 quarters · filed 2022-11-03 | -$1.17M 10-Q · filed 2022-11-03 | |||
| 2021-06-30 | -$224.00K 10-Q · filed 2022-08-04 | -$800.00K 10-Q · filed 2022-08-04 | ||||
| 2021-03-31 | -$576.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |